Patents Examined by Lora E Barnhart
-
Patent number: 9234897Abstract: Disclosed is a method for distinguishing a mesenchymal stem cell comprising, using at least one gene selected from the genes having the nucleotide sequences indicated by the accession numbers shown in Table 1 as a distinguish marker, detecting the difference in expression of the distinguish marker between a mesenchymal stem cell and a connective tissue cell to distinguish the mesenchymal stem cell from the connective tissue cell. This method enables to distinguish an undifferentiated mesenchymal stem cell from other connective tissue cell such as fibroblasts, osteoblasts, chondrocytes and adipose cells with good accuracy. A mesenchymal stem cell given by this method or a composition comprising the mesenchymal stem sell can be used as a therapeutic for use in the regenerative medicine.Type: GrantFiled: March 30, 2006Date of Patent: January 12, 2016Assignee: TWO CELLS CO., LTDInventors: Yukio Kato, Takeshi Kawamoto, Koichiro Tsuji, Akira Igarashi, Masakazu Shimizu
-
Patent number: 9222111Abstract: To provide a method for supplying lauric acid with algae. A method for producing an oil or fat containing lauric acid as a constituent fatty acid including: culturing, in a medium, at least one species of algae in the class Cryptophyceae selected from the group consisting of algae belonging to the genus Rhodomonas and algae belonging to the genus Chroomonas selected from among Chroomonas diplococca, Chroomonas mesostigmatica, Chroomonas nordstedtii, and Chroomonas placoidea and recovering, from the culture product, an oil or fat having a lauric acid content of 3 weight % or higher of the fatty acid composition.Type: GrantFiled: March 24, 2011Date of Patent: December 29, 2015Assignee: Kao CorporationInventors: Hiroshi Yoshida, Fumikazu Takahashi, Yasushi Takimura
-
Patent number: 9211306Abstract: The present invention relates to a cellular therapeutic agent for treating urinary incontinence, and more particularly to a cellular therapeutic agent for treating urinary incontinence, which contains stem cells derived from the decidua of the placenta or menstrual fluid or stem cells derived from adipose. The decidua-derived stem cells or adipose-derived stem cells show the effects of increasing leak point pressure and urethral sphincter contractility, and thus are useful as an agent for treating urinary incontinence.Type: GrantFiled: January 10, 2013Date of Patent: December 15, 2015Assignee: RNL BIO CO., LTD.Inventors: Jeong Chan Ra, Hang Young Lee, Jung Youn Jo, Yun Jung Kim
-
Patent number: 9205276Abstract: The present invention generally relates to a method of using light treatment supporting specific cell types in a subject. Specifically, the present invention relates to methods for stimulating the proliferation, migration, differentiation and survival of cell using specific parameter of lights. These methods are particularly useful in the cellular regeneration and replacement in a tissue injury, such as CNS or PNS injury, and in transplantation of organs, tissues and cells.Type: GrantFiled: March 30, 2006Date of Patent: December 8, 2015Assignees: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND SERVICESInventors: Tara B. Romanczyk, Juanita J. Anders, Ronald R. Waynant, Ilko K. Ilev, Leonardo Longo
-
Patent number: 9192629Abstract: The invention is directed to isolated renal cells, including tubular and erythropoietin (EPO)-producing kidney cell populations, and methods of isolating and culturing the same, as well as methods of treating a subject in need with the cell populations.Type: GrantFiled: October 26, 2012Date of Patent: November 24, 2015Assignee: REGENMEDTX, LLCInventors: Sharon C. Presnell, Andrew Bruce, Shay M. Wallace, Sumana Choudhury, Russell W. Kelley, Manuel J. Jayo, Jessica J. Reinsch, Patricia D. Tatsumi, Timothy A. Bertram, Eric S. Werdin, Oluwatoyin A. Knight, H. Scott Rapoport, Roger M. Ilagan
-
Patent number: 9149497Abstract: Methods and systems for regenerating damaged tissue rely on direct injection of selected therapeutic cells into a tissue at or near the site of tissue damage. Direct injection is accomplished using an intravascular catheter having a deployable needle, and injection is usually targeted into the adventitial and peri-adventitial tissues surrounding the blood vessel from which the needle is deployed.Type: GrantFiled: September 26, 2008Date of Patent: October 6, 2015Assignee: Mercator MedSystems, Inc.Inventors: Kirk Patrick Seward, Lynn Mateel Barr, Robert Cafferata
-
Patent number: 9127252Abstract: The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1 and TWIST but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and the differentiated stem cells, are also provided.Type: GrantFiled: March 13, 2013Date of Patent: September 8, 2015Assignee: The Brigham and Women's Hospital, Inc.Inventors: Keith D. Crawford, Christopher Southgate
-
Patent number: 9115341Abstract: An object of the present invention is to expand CD34+ cells ex vivo efficiently in a short term using a biologically safe and inexpensively obtainable low molecular weight compound. A still another object of the present invention is to provide an expansion agent for CD34+ cells useful for treatment of various hematopoietic disorders caused by dysfunctional hematopoietic stem cells and/or hematopoietic progenitor cells. A method for expanding CD34+ cells, which comprises culturing CD34+ cells ex vivo in the presence of a compound represented by the formula (I) (wherein A, B, L1, L2, L3, L4, R1, R2, R3, X and Y are defined in the description), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof.Type: GrantFiled: December 5, 2008Date of Patent: August 25, 2015Assignee: Nissan Chemical Industries, Ltd.Inventors: Takanori Nakamura, Atsushi Miyamura, Taito Nishino, Norihisa Ishiwata, Katsuaki Miyaji
-
Patent number: 9115344Abstract: Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.Type: GrantFiled: May 25, 2012Date of Patent: August 25, 2015Assignees: NC MEDICAL RESEARCH INC., ASKA PHARMACEUTICAL CO., LTD., MITSUI SUMITOMO INSURANCE CARE NETWORK CO., LTD.Inventors: Osamu Honmou, Kazuo Hashi, Teiji Uede
-
Patent number: 9109202Abstract: The invention provides means and methods for stem cell proliferation and subsequent generation and expansion of progenitor cells. The invention in particular provides media and other culture conditions for the same. The cells are preferably used as effector cells as clinical therapeutics.Type: GrantFiled: September 28, 2006Date of Patent: August 18, 2015Assignee: IPD-THERAPEUTICS B.V.Inventor: Jan Spanholtz
-
Patent number: 9109245Abstract: Disclosed herein are cell culture compositions, for example, pancreatic cell culture compositions, derived from dedifferentiated human reprogrammed pluripotent stem cells, such as induced pluripotent stem (iPS) cells, and methods for producing and using such cell culture compositions.Type: GrantFiled: February 6, 2013Date of Patent: August 18, 2015Assignee: ViaCyte, Inc.Inventors: Alan D. Agulnick, Olivia Kelly, Yuki Ohi, Allan Robins, Thomas Schultz
-
Patent number: 9101608Abstract: The instant invention is the storage of Type II collagen containing tissue in carbonated water. Such Type II collagen is useful for alleviating the symptoms of arthritis in mammals as well as the treatment of arthritis in mammals. Such Type II collagen is also useful for the prevention of arthritis in mammals. The instant invention is also a method for the preparation of a nutritional supplement that includes the steps of: (a) separating water-insoluble undenatured Type II collagen containing animal tissue from animal tissue not containing Type II collagen; (b) subdividing and sterilizing said tissue under conditions which do not change the original structure of the Type II collagen to produce a subdivided and sterilized product; (c) packaging the subdivided and sterilized product in carbonated water.Type: GrantFiled: May 15, 2013Date of Patent: August 11, 2015Assignee: CARTILAST II LLCInventor: Eugene R. Moore
-
Patent number: 9085792Abstract: The present invention relates to a method for inoculating at least one agar culture medium, contained in a Petri dish, with at least one sample likely to contain microorganisms. The method includes the steps of: providing at least one agar culture medium contained in a Petri dish; providing the sample likely to contain microorganisms in liquid form; performing at least one deposition of the liquid sample onto the lid of the Petri dish such that the liquid sample can be transferred from the lid to the agar culture medium; and spraying the liquid sample, initially deposited onto the cover, onto the agar culture medium by vibrating the Petri dish.Type: GrantFiled: August 30, 2012Date of Patent: July 21, 2015Assignee: BIOMERIEUXInventors: Bruno Colin, Marie-Pierre Montet
-
Patent number: 9034316Abstract: The described invention provides pharmaceutical compositions for treating an infarct area injury and methods of treating or repairing the infarct area injury in a revascularized subject in the aftermath of an acute myocardial infarction resulting from a natural disease process by administering to the subject parenterally through a catheter a sterile pharmaceutical composition containing a therapeutically effective amount of a nonexpanded sterile isolated chemotactic hematopoietic stem cell product as a first therapeutic agent and optionally a therapeutically effective amount of at least one compatible second therapeutic agent. The infarct area-improving amount of the sterile isolated chemotactic hematopoietic stem cell product comprises an enriched population of isolated autologous CD34+ cells containing a subpopulation of potent cells expressing CXCR-4 and having CXCR-4-mediated chemotactic activity such that the enriched population of isolated autologous CD34+ hematopoietic stem cells provides at least 0.Type: GrantFiled: December 2, 2009Date of Patent: May 19, 2015Assignee: Amorcyte, LLCInventors: Andrew Pecora, Robert Preti
-
Patent number: 9023416Abstract: The instant invention is the storage of Type II collagen containing tissue in carbonated water. Such Type II collagen is useful for alleviating the symptoms of arthritis in mammals as well as the treatment of arthritis in mammals. Such Type II collagen is also useful for the prevention of arthritis in mammals. The instant invention is also a method for the preparation of a nutritional supplement that includes the steps of: (a) separating water-insoluble undenatured Type II collagen containing animal tissue from animal tissue not containing Type II collagen; (b) subdividing and sterilizing said tissue under conditions which do not change the original structure of the Type II collagen to produce a subdivided and sterilized product; (c) packaging the subdivided and sterilized product in carbonated water.Type: GrantFiled: January 23, 2013Date of Patent: May 5, 2015Assignee: Cartilast II LLCInventor: Eugene R. Moore
-
Patent number: 9011899Abstract: Devices and methods for transplanting cells in a host body are described. The cell comprises a porous scaffold that allows ingrowth of vascular and connective tissues, a plug or plug system configured for placement within the porous scaffold, and a seal configured to enclose a proximal opening in the porous scaffold. The device may further comprise a cell delivery device for delivering cells into the porous scaffold. The method of cell transplantation comprises a two step process. The device is incubated in the host body to form a vascularized collagen matrix around a plug positioned within the porous scaffold. The plug is then retracted from the porous scaffold, and cells are delivered into the vascularized space created within the porous scaffold.Type: GrantFiled: August 27, 2010Date of Patent: April 21, 2015Assignee: Sernova CorporationInventors: Craig Hasilo, Justin Leushner, Daniel Nicholas Haworth, Simon Shohet, Philip Michael Toleikis, Delfina Maria Mazzuca Siroen
-
Patent number: 8940535Abstract: Methods and compositions are provided for isolation of proliferating cells. In particular, the methods enrich stem cells in a mixture of stem cells and non-stem cells, and in some cases the non-stem cells may be differentiated cells. The methods exploit the non-adherent property of stem cells, as opposed to the adherent property of differentiating cells, by serially passaging the suspended cells in liquid media.Type: GrantFiled: November 4, 2004Date of Patent: January 27, 2015Assignees: University of Maryland, Baltimore, The United States of America as Represented by the Dept of Veterans AffairsInventors: G. David Trisler, Christopher T. Bever, Jr., James E. Goolsby, Bernard M. Pessac
-
Patent number: 8920828Abstract: Devices for the treatment of intervertebral discs are described. The devices, when implanted into the nucleus pulposus of an intervertebral disc, provide for the controlled release of one or more active agents into the disc. The active agent can be a chemonucleolytic agent such as chymopapain. The device can also comprise one or more binders. The device can be an elongate solid body having a tapered or rounded insertion end. Alternatively, the device can include a plurality of particles. For devices containing multiple active agents, the configuration of the device be chosen to provide for the sequential or simultaneous release of each of the active agents. The elongate solid body can include a sheath comprising a first active agent and a core comprising a second active agent.Type: GrantFiled: November 29, 2006Date of Patent: December 30, 2014Assignee: Warsaw Orthopedic, Inc.Inventor: Hai H. Trieu
-
Patent number: 8906684Abstract: Provided are methods of the production of patterned 3-dimensional biopolymer scaffolds containing living cells. The methods include selective photopolymerization of biopolymers to create patterned structures and the patterning of cells within relatively homogenous slabs of biopolymer using dielectrophoresis. Also provided are patterned 3-dimensional biopolymer scaffolds generated by the methods and their use.Type: GrantFiled: January 12, 2005Date of Patent: December 9, 2014Assignee: The Regents of the University of CaliforniaInventors: Sangeeta N. Bhatia, Valerie Liu Tsang, Dirk R. Albrecht
-
Patent number: 8889411Abstract: The present invention relates to methods of modulating mammalian stem cell and progenitor cell differentiation. The methods of the invention can be employed to regulate and control the differentiation and maturation of mammalian, particularly human stem cells along specific cell and tissue lineages. The methods of the invention relate to the use of certain small organic molecules to modulate the differentiation of stem or progenitor cell populations along specific cell and tissue lineages, and in particular, to the differentiation of embryonic-like stem cells originating from a postpartum placenta or for the differentiation of early progenitor cells to a granulocytic lineage. Finally, the invention relates to the use of such differentiated stem or progenitor cells in transplantation and other medical treatments.Type: GrantFiled: March 2, 2009Date of Patent: November 18, 2014Assignee: Anthrogenesis CorporationInventors: Robert J. Hariri, David I. Stirling, Laure A. Moutouh-De Parseval, Kyle W. H. Chan